126.20
price down icon0.05%   -0.06
after-market アフターアワーズ: 126.08 -0.12 -0.10%
loading
前日終値:
$126.26
開ける:
$126.65
24時間の取引高:
5.90M
Relative Volume:
3.55
時価総額:
$13.41B
収益:
$612.78M
当期純損益:
$-86.37M
株価収益率:
-145.06
EPS:
-0.87
ネットキャッシュフロー:
$-62.91M
1週間 パフォーマンス:
+33.02%
1か月 パフォーマンス:
+45.12%
6か月 パフォーマンス:
+64.95%
1年 パフォーマンス:
+91.36%
1日の値動き範囲:
Value
$126.16
$126.73
1週間の範囲:
Value
$126.00
$128.00
52週間の値動き範囲:
Value
$62.78
$128.00

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name
名前
Intra Cellular Therapies Inc
Name
セクター
Healthcare (1174)
Name
電話
(646) 440-9333
Name
住所
135 ROUTE 202/206, BEDMINSTER, NY
Name
職員
561
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
ITCI's Discussions on Twitter

ITCI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
126.20 13.41B 612.78M -86.37M -62.91M -0.87
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.89 74.84B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.24 41.78B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
12.92 40.96B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
21.92 24.83B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
143.26 14.50B 2.24B 385.90M 440.10M 3.73

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-09-06 アップグレード Piper Sandler Neutral → Overweight
2024-01-03 開始されました Robert W. Baird Outperform
2023-12-11 開始されました TD Cowen Outperform
2023-04-20 開始されました Morgan Stanley Overweight
2022-08-22 ダウングレード Goldman Buy → Neutral
2022-07-07 開始されました Mizuho Buy
2022-06-14 開始されました UBS Buy
2022-04-22 開始されました Piper Sandler Neutral
2022-02-16 開始されました Goldman Buy
2021-09-23 開始されました Needham Buy
2020-12-15 開始されました BofA Securities Buy
2020-12-10 開始されました Goldman Buy
2020-02-20 開始されました Evercore ISI Outperform
2020-01-31 ダウングレード JP Morgan Overweight → Neutral
2019-12-24 繰り返されました Canaccord Genuity Buy
2019-08-12 開始されました Jefferies Buy
2018-02-26 開始されました JP Morgan Overweight
2018-02-08 開始されました RBC Capital Mkts Outperform
2017-12-15 開始されました Canaccord Genuity Buy
2017-11-08 アップグレード SunTrust Hold → Buy
2017-09-07 アップグレード Piper Jaffray Neutral → Overweight
2017-08-30 アップグレード Ladenburg Thalmann Neutral → Buy
2017-08-24 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2017-08-23 アップグレード Leerink Partners Mkt Perform → Outperform
2017-05-02 ダウングレード Ladenburg Thalmann Buy → Neutral
2017-05-02 ダウングレード Leerink Partners Outperform → Mkt Perform
2017-05-01 ダウングレード Piper Jaffray Overweight → Neutral
2016-12-16 開始されました Cantor Fitzgerald Overweight
2016-09-29 繰り返されました RBC Capital Mkts Outperform
2016-09-29 ダウングレード SunTrust Buy → Neutral
すべてを表示

Intra Cellular Therapies Inc (ITCI) 最新ニュース

pulisher
04:27 AM

3,043 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Avanza Fonder AB - MarketBeat

04:27 AM
pulisher
Jan 19, 2025

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - Insider Monkey

Jan 19, 2025
pulisher
Jan 19, 2025

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga

Jan 19, 2025
pulisher
Jan 19, 2025

Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey

Jan 18, 2025
pulisher
Jan 18, 2025

Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey

Jan 18, 2025
pulisher
Jan 17, 2025

J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga

Jan 17, 2025
pulisher
Jan 17, 2025

Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN

Jan 17, 2025
pulisher
Jan 16, 2025

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World

Jan 16, 2025
pulisher
Jan 16, 2025

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders - MSN

Jan 16, 2025
pulisher
Jan 15, 2025

J&J to buy Intra-Cellular for $132/share in cash - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Johnson & Johnson Is Exploring Bid for Intra-Cellular Therapies - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Why Johnson & Johnson Is Buying Intra-Cellular Therapies In A $14.6 Billion Deal - Pulse 2.0

Jan 15, 2025
pulisher
Jan 15, 2025

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn - BioXconomy

Jan 15, 2025
pulisher
Jan 15, 2025

J&J’s Top Rating at Risk Because of Intra-Cellular Deal - Bloomberg

Jan 15, 2025
pulisher
Jan 15, 2025

Johnson & Johnson to acquire Intra-Cellular Therapies for $14.6bn - World Pharmaceutical Frontiers

Jan 15, 2025
pulisher
Jan 15, 2025

Baird R W Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Leerink Partnrs Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Cantor Fitzgerald Upgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Strong-Buy - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK And Intra-Cellular - Barchart

Jan 15, 2025
pulisher
Jan 15, 2025

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular - Yahoo Finance

Jan 15, 2025
pulisher
Jan 15, 2025

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion - European Biotechnology News

Jan 15, 2025
pulisher
Jan 15, 2025

Piper Sandler Downgrades Intra-Cellular Therapies (ITCI) - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion - Medical Dialogues

Jan 15, 2025
pulisher
Jan 14, 2025

J&J strikes $14.6 billion deal for Intra-Cellular Therapies - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Johnson & Johnson's 'AAA' rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

J&J Is in Talks to Buy $10 Billion Biotech Intra-Cellular - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

Johnson & Johnson Bolsters Neuroscience Offerings with $14.6 Billion Acquisition of Intra-Cellular Therapies - Hoodline

Jan 14, 2025
pulisher
Jan 14, 2025

Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - Investing News Network

Jan 14, 2025
pulisher
Jan 14, 2025

Intra-Cellular Therapies' (ITCI) Neutral Rating Reiterated at Piper Sandler - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

J&J to leverage Intra-Cellular Therapies’ neurology portfolio - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Sees Large Volume IncreaseTime to Buy? - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Johnson & Johnson acquires Intra-Cellular for $14.6bn - OutSourcing-Pharma.com

Jan 14, 2025
pulisher
Jan 14, 2025

Cravath, Davis Polk advise on Johnson & Johnson’s $14.6bn Intra-Cellular acquisition - The Global Legal Post

Jan 14, 2025
pulisher
Jan 14, 2025

Intra-Cellular Therapies stock jumps 34%: Can it ride the wave? - Dataconomy

Jan 14, 2025
pulisher
Jan 14, 2025

ITCI Poised for Turnaround Amid Rising Mental Health Concerns - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition - PMLiVE

Jan 14, 2025
pulisher
Jan 14, 2025

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last? - Yahoo Finance

Jan 14, 2025

Intra Cellular Therapies Inc (ITCI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$11.30
price down icon 0.35%
$143.26
price up icon 0.94%
$91.47
price down icon 0.12%
$12.02
price up icon 0.08%
$29.47
price down icon 0.94%
大文字化:     |  ボリューム (24 時間):